University of Vermont
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1791-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.uvm.edu
Clinical Trials
211
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (185 trials with phase data)• Click on a phase to view related trials
Clinical Screening and Peer Interventions to Prevent Substance Use in At-Risk Adolescents
- Conditions
- Initation of Substance Use Disorder
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 50
- Registration Number
- NCT07074860
A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML
- Conditions
- AML - Acute Myeloid Leukemia
- Interventions
- Drug: Dexamethasone plus Venetoclax-based Low-Intensity Therapy
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 20
- Registration Number
- NCT07014462
- Locations
- 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States
DOAC - Dosing Options in AntiCoagulation Prophylaxis
- Conditions
- CancerVTE (Venous Thromboembolism)
- Interventions
- Drug: Apixaban 2.5 mg twice dailyDrug: Apixaban 5 mg once dailyDrug: No anticoagulation
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 996
- Registration Number
- NCT07005024
- Locations
- 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States
A Multi-Site Hybrid Type I Effectiveness-Implementation Randomized Trial of an Emergency Care Action Plan for Infants With Medical Complexity
- Conditions
- Chronic Disease ManagementUtilization, Health CareCaregiver StressInfants HealthEmergency
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 500
- Registration Number
- NCT06993129
- Locations
- 🇺🇸
Colorado Children's Hospital, Aurora, Colorado, United States
🇺🇸Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer
- Conditions
- Prostate CAAndrogen Deprivation Therapy
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 32
- Registration Number
- NCT06972875
- Locations
- 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 43
- Next
News
Probiotic Supplementation Reduces Mortality in Preterm Infants, Canadian Study Shows
A large Canadian retrospective study of 32,667 preterm infants reveals probiotics significantly reduced mortality rates, with an adjusted odds ratio of 0.62 in infants born before 34 weeks gestation.